This proposal is written in response to an NHLBI FOA requesting a Data Coordinating Center (DCC) for RFA-HL-08-003 Mechanisms and Management of Cardiovascular and Metabolic Complications of HIV/AIDS. The purpose of the FOA is to foster collaborative research to elucidate the underlying mechanisms of metabolic and anthropometric abnormalities seen in HIV infection and highly active antiretroviral therapy and their relationship to cardiovascular disease risk. In this application, we propose to run the DCC from the Collaborative Health Studies Coordinating Center (CHSCC) at the University of Washington. The DCC will be responsible for coordinating studies at 6-7 clinical sites engaged in separate, but complimentary research agendas. Although the studies will all involve research that addresses the title of this RFA, the size and scope of these studies has yet to be fully determined. The DCC will play a key role in coordination and management of these studies. Its key responsibilities will include facilitation of data harmonization, standardization of study protocols where appropriate, facilitating data and specimen banking, scheduling and facilitating investigator meetings, coordinating centralized readings of cardiac evaluations and providing statistical expertise and support in protocol development, data analysis and preparation of presentations and manuscripts. This application describes our relevant experience and preparedness in these areas as well as others crucial to efficiently running a DCC. It also presents our plans for running the DCC for this group of studies. HIV-infected individuals have increased life expectancies since the introduction of highly active antiretroviral therapy (HAART). With this increased life expectancy come increased incidences of metabolic complications and cardiovascular disease (CVD) associated with living with HIV/AIDS and prolonged exposure to HAART. Studying how these diseases interact with HIV and HAART can help prevent their development and progression in HIV-infected individuals.
HIV-infected individuals have increased life expectancies since the introduction of highly active antiretroviral therapy (HAART). With this increased life expectancy come increased incidences of metabolic complications and cardiovascular disease (CVD) associated with living with HIV/AIDS and prolonged exposure to HAART. Studying how these diseases interact with HIV and HAART can help prevent their development and progression in HIV-infected individuals.
|Kelesidis, Theodoros; Tran, Thuy Tien T; Brown, Todd T et al. (2017) Changes in plasma levels of oxidized lipoproteins and lipoprotein subfractions with atazanavir-, raltegravir-, darunavir-based initial antiviral therapy and associations with common carotid artery intima-media thickness: ACTG 5260s. Antivir Ther 22:113-126|
|Bhagwat, Priya; Ofotokun, Ighovwerha; McComsey, Grace A et al. (2017) Changes in abdominal fat following antiretroviral therapy initiation in HIV-infected individuals correlate with waist circumference and self-reported changes. Antivir Ther 22:577-586|
|Erlandson, Kristine M; Fiorillo, Suzanne; Masawi, Fadzai et al. (2017) Antiretroviral initiation is associated with increased skeletal muscle area and fat content. AIDS 31:1831-1838|
|Kelesidis, Theodoros; Jackson, Nicholas; McComsey, Grace A et al. (2016) Oxidized lipoproteins are associated with markers of inflammation and immune activation in HIV-1 infection. AIDS 30:2625-2633|
|McComsey, Grace A; Moser, Carlee; Currier, Judith et al. (2016) Body Composition Changes After Initiation of Raltegravir or Protease Inhibitors: ACTG A5260s. Clin Infect Dis 62:853-62|
|Kelesidis, Theodoros; Moser, Carlee; Stein, James H et al. (2016) Changes in Markers of T-Cell Senescence and Exhaustion With Atazanavir-, Raltegravir-, and Darunavir-Based Initial Antiviral Therapy: ACTG 5260s. J Infect Dis 214:748-52|
|McKibben, Rebeccah A; Haberlen, Sabina A; Post, Wendy S et al. (2016) A Cross-sectional Study of the Association Between Chronic Hepatitis C Virus Infection and Subclinical Coronary Atherosclerosis Among Participants in the Multicenter AIDS Cohort Study. J Infect Dis 213:257-65|
|Parikh, Rushi V; Ma, Yifei; Scherzer, Rebecca et al. (2016) Endothelin-1 Predicts Hemodynamically Assessed Pulmonary Arterial Hypertension in HIV Infection. PLoS One 11:e0146355|
|Dirajlal-Fargo, Sahera; Moser, Carlee; Brown, Todd T et al. (2016) Changes in Insulin Resistance After Initiation of Raltegravir or Protease Inhibitors With Tenofovir-Emtricitabine: AIDS Clinical Trials Group A5260s. Open Forum Infect Dis 3:ofw174|
|McKibben, Rebeccah A; Margolick, Joseph B; Grinspoon, Steven et al. (2015) Elevated levels of monocyte activation markers are associated with subclinical atherosclerosis in men with and those without HIV infection. J Infect Dis 211:1219-28|
Showing the most recent 10 out of 30 publications